Company intelligence / Profile preview

SimmonsCooper

Lagos, Lagos, Nigeria

Ownership: Private
Employees: ~50
Development stage: Other

Overview

SimmonsCooper Partners is a leading law firm and consultancy that provides specialized legal and regulatory services within the health and life sciences sectors. The firm is particularly recognized for its expertise in healthcare compliance, pharmaceutical regulation, and medical litigation, including high-profile cases related to asbestos exposure and mesothelioma. Beyond litigation, the firm advises biotechnology and pharmaceutical companies on market entry, intellectual property protection, and clinical trial regulations. Their multidisciplinary approach combines legal strategy with industry-specific knowledge to support healthcare providers and life science innovators. The firm operates globally with a significant presence in emerging markets, particularly in West Africa.

Therapeutic areas: Oncology
Industry: Consulting

Beyond the preview

Go deeper on SimmonsCooper.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SimmonsCooper.

Explore the full profile